su14813
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2003 (NCT00982267)
Timeline
Indications
Mechanism of action
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
FLT3 inhibitor
Vascular endothelial growth factor receptor inhibitor
Platelet-derived growth factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1- Mol. weight
- 442.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545160 ↗
- ChEMBLCHEMBL1721885 ↗
Also known as
- 5-((5-fluoro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl)-n-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide
- su014813
- su-014813
- su-014813
- su14813
- su 14813
- su-14813
- su-14813
- su-14813
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00322517 | Phase 2 | Apr 1, 2006 | Pfizer |
| NCT00982267 | Phase 1 | Dec 1, 2003 | Pfizer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 2 | 2003 |
1 organizations
Page 1 / 1